A carregar...
The optimal timing and courses of bevacizumab added to chemotherapy for non-squamous non-small cell lung cancer: revelations from the real-world experience in a single Chinese cancer center
BACKGROUND: Bevacizumab combined with platinum-based chemotherapy has been approved in the first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) without driver genes, but this regimen for second-line or later-line treatment of non-squamous NSCLC remains to be further test...
Na minha lista:
| Publicado no: | Ann Transl Med |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7661884/ https://ncbi.nlm.nih.gov/pubmed/33209891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-6327 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|